Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative antiviral therapeutics targeting serious viral diseases, including hepatitis C, influenza, and norovirus infections. Utilizing advanced structure-based technologies, the company is developing CC-31244, a non-nucleoside polymerase inhibitor currently undergoing Phase 2a clinical trials for hepatitis C. Additionally, Cocrystal is advancing CC-42344, a PB2 inhibitor for influenza, which is in preclinical development. The company has established research collaborations, including an exclusive agreement with Merck Sharp & Dohme Corp. to develop proprietary antiviral agents for influenza A and B, as well as a license with Kansas State University Research Foundation to create antiviral treatments for norovirus and coronavirus infections. Headquartered in Bothell, Washington, Cocrystal Pharma continues to explore and develop promising antiviral compounds using its proprietary drug design technology.